Suzhou Zelgen Biopharmaceuticals Co., Ltd.
SSE:688266.SS
114.92 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | |||||||||
| Net Income
| -150.298 | -295.135 | -485.949 | -461.991 | -310.675 | -447.984 | -441.877 | -146.468 | -128.268 |
| Depreciation & Amortization
| 55.599 | 54.83 | 66.369 | 50.771 | 34.719 | 33 | 13.844 | 4.968 | 5.733 |
| Deferred Income Tax
| 0 | 0 | -2.443 | -3.631 | -4.08 | -4.347 | -0.78 | 0 | 0 |
| Stock Based Compensation
| 0 | 0 | 37.066 | 34.623 | 31.12 | 237.445 | 309.051 | 0 | 68.02 |
| Change In Working Capital
| 155.091 | 24.526 | 0.219 | -77.603 | -88.344 | -3.062 | 14.829 | 35.017 | -1.157 |
| Accounts Receivables
| -58.167 | -38.354 | -17.412 | -84.191 | -20.87 | -11.007 | -3.863 | -4.114 | -9.31 |
| Inventory
| -72.009 | -11.874 | -47.067 | -28.773 | -16.713 | -3.872 | -2.074 | -0.314 | -0.074 |
| Accounts Payables
| 0 | 78.494 | 67.141 | 38.993 | -46.68 | 16.164 | 21.546 | 39.446 | 8.227 |
| Other Working Capital
| 285.267 | -3.739 | -2.443 | -3.631 | -4.08 | -4.347 | 16.903 | 35.332 | -1.082 |
| Other Non Cash Items
| -22.187 | -4.534 | 14.396 | 3.208 | -6.597 | 4.519 | 300.767 | -1.768 | 66.971 |
| Operating Cash Flow
| 38.205 | -220.313 | -370.343 | -454.623 | -343.857 | -180.428 | -112.437 | -108.252 | -56.72 |
| Investing Activities: | |||||||||
| Investments In Property Plant And Equipment
| -95.69 | -62.601 | -88.624 | -70.739 | -57.681 | -15.105 | -11.081 | -11.657 | -24.32 |
| Acquisitions Net
| 0 | 0 | -24.222 | -8.357 | 57.681 | 15.105 | -15.458 | 0 | 24.32 |
| Purchases Of Investments
| -2,966.5 | -1,135 | -943.097 | -520 | -1,135.01 | -195 | -344.9 | -121 | -226 |
| Sales Maturities Of Investments
| 1,217.089 | 1,250 | 767.661 | 917.395 | 693.437 | 273.434 | 317.598 | 122.951 | 192.894 |
| Other Investing Activites
| -0 | 0.003 | 24.226 | 8.357 | -57.681 | -15.105 | 0.729 | 0.88 | -24.32 |
| Investing Cash Flow
| -1,845.101 | 52.401 | -264.056 | 326.657 | -499.253 | 63.329 | -53.113 | -8.827 | -57.426 |
| Financing Activities: | |||||||||
| Debt Repayment
| 153.479 | 353.8 | 318.234 | 106.492 | -12.35 | 60 | 0 | 0 | 0 |
| Common Stock Issued
| 0 | -1.446 | 0 | 0 | -113.1 | -4.542 | 0 | 0 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 4.542 | 0 | 0 | 0 |
| Dividends Paid
| -24.564 | -21.175 | -11.216 | -4.141 | -1.111 | -1.16 | 0 | 0 | 0 |
| Other Financing Activities
| -180.232 | 1,176.741 | -24.226 | -8.357 | 1,912.5 | 0.021 | 285.375 | 110.056 | 124.789 |
| Financing Cash Flow
| -51.316 | 1,509.366 | 282.792 | 93.994 | 1,899.039 | 54.318 | 285.375 | 110.056 | 124.789 |
| Other Information: | |||||||||
| Effect Of Forex Changes On Cash
| -2.298 | 0.217 | 4.068 | -1.438 | -3.794 | 0.769 | -0.777 | -0.118 | 0.054 |
| Net Change In Cash
| -1,860.512 | 1,341.671 | -347.539 | -35.41 | 1,052.135 | -62.012 | 119.048 | -7.141 | 10.697 |
| Cash At End Of Period
| 217.265 | 2,077.777 | 736.106 | 1,083.645 | 1,119.055 | 66.92 | 128.932 | 9.885 | 17.025 |